Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Adaptive Biotechnologies Corporation develops immune medicine products leveraging proprietary next-generation sequencing and machine learning to decode the adaptive immune system. Its core offerings include clonoSEQ, an FDA-authorized assay for detecting minimal residual disease (MRD) in lymphoid cancers, serving clinicians and biopharmaceutical partners. The company also advances immune-based therapies for cancer and autoimmune diseases through its extensive immunosequencing platform, large clinical database, and collaborations with pharmaceutical firms.
This description was generated via AI from an annual report. Updated about 1 year ago.